Press Release FeedGet the RSS feed
Menu

Business Wire

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

Bristol-Myers Squibb

  • Tempus to build a de-identified dataset from hundreds of thousands of patients with neurological conditions; Pathos to license the dataset under a five-year, $55 million agreement

  • Pathos's AI expertise and agentic AI platform, Foundry, combined with Bristol Myers Squibb's (BMS) neuroscience drug development expertise to be applied to understanding disease progression and advancing new therapies

  • BMS leads Pathos's Series E financing and gains non-exclusive strategic access to Pathos's AI platform, Pathos Foundry, across its broader portfolio, along with three-year exclusive rights to support its neuroscience development programs

NEW YORK, October 23, 2026--Pathos AI, a clinical-stage AI and technology company advancing its own therapeutic pipeline, today announced multi-year strategic collaborations with Bristol Myers Squibb (NYSE: BMY, "BMS") and Tempus AI, Inc. (NASDAQ: TEM, "Tempus") to build a specialized, curated dataset and agentic AI capabilities for Alzheimer's disease and other neurological conditions. BMS also leads Pathos's Series E financing and gains access to Pathos Foundry across its broader R&D portfolio.

Tempus will apply the infrastructure and expertise it has built in oncology to create a comprehensive, de-identified, longitudinal dataset from hundreds of thousands of patients with neurological conditions, designed to track outcomes over time and accelerate biological insight. Pathos will license the data from Tempus under a five-year, $55 million agreement.

Pathos will apply its AI platform, Pathos Foundry, to interrogate the dataset at scale, generate and test hypotheses on disease biology, and inform the design of more targeted, adaptive clinical trials. Pathos built and validated this approach in oncology, where it guides decisions across the company's clinical-stage pipeline, including adapting trial design in real time to improve its projected probability of success.

The collaboration builds on BMS's broader strategy to combine advanced AI with deep scientific and disease-area expertise to make faster, higher-confidence decisions that drive innovation for patients. BMS is helping expand the application of Pathos Foundry into neuroscience, securing three-year exclusive rights in an area where the company brings deep research, clinical-development expertise and a growing portfolio of programs in Alzheimer's disease and other neurological conditions. Through multi-year access to the platform across its broader portfolio and the specialized dataset developed through the definitive agreements, BMS aims to generate deeper insights into disease progression, identify patients most likely to benefit from potential therapies and design more precise clinical trials.

  1. FinanceBristol Myers SquibbBristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026Companies: Bristol-Myers SquibbData reinforce the potential for immune reset with zolacabtagene autoleucel to address an underlying cause of multiple sclerosis PRINCETON, N.J., October 23, 2026--Bristol Myers Squibb (NYSE: BMY) today announced disclosure of interim safety and efficacy results from the multiple sclerosis (MS) cohort
  2. FinanceTempus AI, Inc.Tempus Expands Strategic Collaboration with Bristol Myers SquibbCompanies: Bristol-Myers SquibbCHICAGO, October 23, 2026--Tempus AI, Inc. (NASDAQ: TEM, "Tempus") today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, "BMS"), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug ta
  3. HealthcareThe Institute for Healthcare ImprovementIHI and Bristol Myers Squibb Launch National Collaborative to Expand Access to Cancer Clinical TrialsCompanies: Bristol-Myers SquibbThree-year initiative will bring clinical research closer to patients and address barriers to trial participation BOSTON, October 22, 2026--The Institute for Healthcare Improvement (IHI), in partnership with Bristol Myers Squibb (BMS), is launching a new Cancer Collective Action Collaborative. This thr
  4. Bristol Myers SquibbBristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026Companies: Bristol-Myers SquibbLate-breaking Phase 3 disclosures for izalontamab brengitecan (iza-bren), a potential first-in-class EGFR × HER3 bispecific ADC, in EGFR-mutated non-small cell lung cancer (PANKU-Lung01) and HR+/HER2- breast cancer (PANKU-Breast01) Late-breaking Phase 2 global data presentation for pumitamig, a PD-L1 × VEGF-A bispecific i
  5. HealthcareBristol Myers SquibbOn the 12th Edition of Global Patient Week Bristol Myers Squibb and Saudi Schizophrenia Association 'Ehtiwaa' Collaborate to Support People Living with Schizophrenia Through the 'Small Wins' InitiativeCompanies: Bristol-Myers SquibbReinforcing its commitment to putting patients at the centre of everything it does, Bristol Myers Squibb (BMS), a leading global biopharmaceutical...
  6. HealthcareBristol Myers SquibbOn the 12th Edition of Global Patient Week Bristol Myers Squibb and Saudi Schizophrenia Association 'Ehtiwaa' Collaborate to Support People Living with Schizophrenia Through the 'Small Wins' InitiativeCompanies: Bristol-Myers SquibbMore than 70 personalized 'Small Wins' toolkits, assembled by Bristol Myers Squibb employees, were designed to encourage everyday engagement, self-recognition and emotional well-being among people living with schizophrenia in Saudi Arabia. RIYADH, Saudi Arabia, Oct. 12, 2026...